Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

266
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
266
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

364
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

3
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
3
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

3
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
3
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

367
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
367
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemodynamic Assessment in Newborn Infants With Sepsis: A Prospective Observational Study.

Cureus·2026
Same author

Risk Factors Associated With Febrile Seizures in Young Children: Clinical, Biochemical, and Genetic Perspectives.

Cureus·2026
Same author

The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial.

Hepatology communications·2026
Same author

Caregiver Involvement and Burden and Patient Quality of Life in Patients with Decompensated Cirrhosis.

The American journal of gastroenterology·2026
Same author

Neonatal Conjugated Hyperbilirubinemia: Clinical Profile, Etiology, and Predictors of Adverse Outcomes in a NICU of a Tertiary Care Center.

Cureus·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology international·2026
Same journal

Reviewer Recognition.

Clinical and translational gastroenterology·2026
Same journal

Cost effectiveness of modalities of Palliative Biliary Drainage in Malignant Extrahepatic Biliary Obstruction.

Clinical and translational gastroenterology·2026
Same journal

Beyond the Count: Critical Gaps in Intraepithelial Lymphocyte-Based Progression Markers of Potential Autoimmune Gastritis.

Clinical and translational gastroenterology·2026
Same journal

Short-term mortality is reduced and low grade ACLF reversed by TIPS in patients with fluid overload: a case-control study.

Clinical and translational gastroenterology·2026
Same journal

Response to Jamalinia and Lonardo.

Clinical and translational gastroenterology·2026
Same journal

The impact of obesity on inflammatory cytokines and 90- and 180-day survival in patients with alcohol-associated hepatitis.

Clinical and translational gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.8K

Addressing Alcohol Use Disorder in Alcohol-Associated Liver Disease.

Sheel Patel1, Nimish Thakra2, Akash Shukla3

  • 1Department of Medicine, University of Louisville, Louisville, Kentucky, USA.

Clinical and Translational Gastroenterology
|April 17, 2026
PubMed
Summary
This summary is machine-generated.

Alcohol use disorder (AUD) is a major public health issue, often leading to severe alcohol-associated liver disease (ALD). This review offers clinicians practical strategies for screening and treating AUD in ALD patients to improve outcomes.

Keywords:
AHALDAUDabstinencebrief intervention

More Related Videos

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.5K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.8K

Related Experiment Videos

Last Updated: Apr 19, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.8K
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.5K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.8K

Area of Science:

  • Hepatology
  • Addiction Medicine
  • Public Health

Background:

  • Alcohol use disorder (AUD) is a significant public health concern.
  • Alcohol-associated liver disease (ALD) is the most common organ damage from AUD and is rising globally.
  • Untreated AUD in liver disease patients accelerates liver injury and increases healthcare costs.

Purpose of the Study:

  • To provide clinicians with effective strategies and tools for managing AUD in patients with ALD.
  • To emphasize the importance of screening for and addressing AUD during healthcare encounters.
  • To promote comprehensive, holistic treatment approaches for co-occurring AUD and liver disease.

Main Methods:

  • This is a review article.
  • It synthesizes current clinical practices and evidence for AUD management in liver disease.
  • Strategies focus on screening, diagnosis, and treatment within clinical settings.

Main Results:

  • Effective screening and treatment of AUD can mitigate liver injury progression.
  • Integrated care models improve patient outcomes and reduce healthcare burden.
  • Clinicians require accessible tools to address AUD holistically in ALD patients.

Conclusions:

  • Addressing AUD is critical for managing ALD and improving patient outcomes.
  • Clinicians should routinely screen for and treat AUD in all patients with liver disease.
  • Comprehensive treatment strategies are essential for patients with alcohol-associated liver disease.